Sanofi and Blackstone enter multimillion-euro partnership on bone marrow cancer drug
Blackstone is committing itself to help Sanofi’s drug, Sarclisa, reach the market in a subcutaneous formulation. A phase III study is slated to begin in a few months.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen
Blackstone Life Sciences, which is part of the Blackstone group, has entered a collaboration with French pharmaceutical firm Sanofi, according to a joint press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Janssen submits Genmab-developed drug for EMA approval
For subscribers
Sanofi pays up to USD 1bn for new multiple myeloma therapy
For subscribers
